Related Experiment Video
Updated: Jul 25, 2025
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Clinical Characteristics of Molecularly Defined Renal Cell Carcinomas
Xinfeng Hu1, Congzhu Tan1, Guodong Zhu1
1Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Abstract:
Kidney tumors comprise a broad spectrum of different histopathological entities, with more than 0.4 million newly diagnosed cases each year, mostly in middle-aged and older men. Based on the description of the 2022 World Health Organization (WHO) classification of renal cell carcinoma (RCC), some new categories of tumor types have been added according to their specific molecular typing. However, studies on these types of RCC are still superficial, many types of these RCC currently lack accurate diagnostic standards in the clinic, and treatment protocols are largely consistent with the treatment guidelines for clear cell RCC (ccRCC), which might result in worse treatment outcomes for patients with these types of molecularly defined RCC. In this article, we conduct a narrative review of the literature published in the last 15 years on molecularly defined RCC. The purpose of this review is to summarize the clinical features and the current status of research on the detection and treatment of molecularly defined RCC.
Insights
New kidney tumor classifications based on molecular typing are emerging, but research and diagnostic standards are lacking. This review summarizes current knowledge on molecularly defined renal cell carcinoma (RCC) detection and treatment.
Area of Science:
- Oncology
- Pathology
- Genetics
Background:
- Kidney tumors represent diverse histopathological entities, with over 0.4 million new cases annually, predominantly in middle-aged to older men.
- The 2022 World Health Organization (WHO) classification introduced new renal cell carcinoma (RCC) categories based on molecular typing.
- Current research on these molecularly defined RCC types is limited, lacking precise diagnostic standards and potentially leading to suboptimal treatment outcomes.
Purpose of the Study:
- To conduct a narrative review of literature from the past 15 years focusing on molecularly defined RCC.
- To consolidate information on the clinical features of molecularly defined RCC.
- To summarize the current research status regarding the detection and treatment of molecularly defined RCC.
Main Methods:
- A comprehensive literature search was performed covering the last 15 years.
- The review focused on studies detailing molecularly defined renal cell carcinoma (RCC).
- Information was synthesized to cover clinical features, detection methods, and treatment strategies.
Main Results:
- The 2022 WHO classification expands RCC categorization with new molecularly defined subtypes.
- Many novel RCC subtypes lack established clinical diagnostic standards.
- Treatment protocols often mirror those for clear cell RCC (ccRCC), potentially impacting efficacy for other subtypes.
Conclusions:
- Molecularly defined RCC subtypes require further investigation to establish accurate diagnostic criteria.
- Tailored treatment strategies are needed for molecularly defined RCC to improve patient outcomes.
- Continued research into molecularly defined RCC is crucial for advancing personalized oncology.
More Related Videos
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
05:36Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
Related Concept Videos
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...